Neurorehabilitation through Hippotherapy on Neurofunctional Sequels of Stroke: Effect on Patients' Functional Independence, Sensorimotor/Cognitive Capacities and Quality of Life, and the Quality of Life of Their Caregivers-A Study Protocol

Brain Sci. 2022 May 9;12(5):619. doi: 10.3390/brainsci12050619.

Abstract

Background: Stroke is a high burden illness and the second leading cause of worldwide disability with generally poor recovery rates. Robust benefits of hippotherapy, a novel neurorehabilitation approach, in functional recovery following various severe neurological disabling conditions has been shown. In the present study, we will analyze the effect of a hippotherapy program on the outcome of post-stroke patients in the first year post-stroke.

Method: A randomized controlled clinical trial on the effectiveness of hippotherapy (4 weeks/18 weeks hippotherapy/conventional neurorehabilitation) versus conventional neurorehabilitation alone (22 weeks) will be conducted over 48 weeks. In the treated group, one-hour daily hippotherapy sessions will be exclusively conducted during the hippotherapy's cycles, alternated with periods of conventional neurorehabilitation. A test battery will measure both the functional and psychological outcomes. The primary endpoint will be the patient's functional independence. The secondary endpoints will measure the sensorimotor function, autonomy, and quality of life, as well as the caregivers' quality of life.

Results and conclusion: Individual brain connectome, life history and personality construct influence the brain's functional connectivity and are central to developing optimal tailored neurorehabilitation strategies. According to our current practice, hippotherapy allows the enhancement of substantial neuroplastic changes in the injured brain with significant neurological recovery. The protocol aims to confirm those issues. Trial registration in ClinicalTrials.gov NCT04759326 accessed on 19 February 2021.

Keywords: autonomy; cerebrovascular accident; functional deficit; hippotherapy; neuroplasticity; neurorehabilitation; quality of life; silent neurofunctional barriers.

Associated data

  • ClinicalTrials.gov/NCT04759326

Grants and funding

This study is supported by the research grants for functioning/health costs for patients’ hippotherapy program/subcontracting from Boehringer Ingelheim and functioning costs from Alliance Equiphoria. The study sponsors and funders, other than Alliance Equiphoria, will not have any role in the study collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication. They will not have any ultimate authority over any of these activities. Only Alliance Equiphoria will have ultimate authority over all these activities.